SYGNIS AG: Molecular Cell publishes the Discovery and Characterization of PrimPol, a new Type of Human DNA Polymerase
(firmenpresse) - (DGAP-Media / 05.11.2013 / 13:17)
Press Release
Molecular Cell publishes the Discovery and Characterization of PrimPol, a
new Type of Human DNA Polymerase
- PrimPol is the latest polymerase cloned from the human genome. The
enzyme displays novel properties with great potential for application
in the field of DNA sequencing and amplification.
- The work has been conducted under the direction of Luis Blanco,
Professor at CSIC in Madrid and currently Scientific Advisor to SYGNIS
AG.
- PrimPol is one of the most innovative products in its field and its
thermostable version one of the principal products in SYGNIS late-stage
pipeline.
Madrid/Heidelberg, 5 November 2013 - SYGNIS AG (Frankfurt: LIO1; ISIN:
DE000A1RFM03; Prime Standard) today announced that Molecular Cell, one of
the scientific journals in the Molecular Biology field with the highest
impact factor, belonging to the same group that publishes 'Cell', has
recently published the paper 'PrimPol, an Archaic Primase/Polymerase
Operating in Human Cells'.
Prof. Luis Blanco, Research Professor at CSIC (Consejo Superior de
Investigaciones Científicas, Madrid), X-Pol co-founder and currently
Scientific Advisor to SYGNIS AG, is the principal investigator behind the
paper, that describes the discovery and characterization of a new type of
DNA polymerase, named PrimPol, cloned from the human genome.
PrimPol is one of the most innovative discoveries in the Molecular Biology
field and one of the key products in SYGNIS AG's portfolio. Luis Blanco
stated: 'I am convinced that this fantastic enzyme will open numerous novel
applications in the field of Molecular Biology, some of them we can only
hint at this moment given the highly innovative potential of its key
features'.
Key features of this enzyme are its duality as a DNA primase and DNA
polymerase, and its high tolerance to damaged DNA. The primase function of
PrimPol allows it to start reading and copying DNA without the need for
providing random primers, as required by all other commercially available
polymerases. Using random primers can bias the sequencing and amplification
results. The polymerase function of PrimPol displays a high specific
activity, being very efficient also when copying DNA with different
lesions.
SYGNIS AG is currently developing a new thermostable version of the enzyme
that will exploit the features described above, offering a distinctive
product with huge potential in the DNA amplification and sequencing field.
The Spanish-German company is proud to point out that the publication of
Prof. Blanco's results in a journal of the impact of Molecular Cell
reflects the high scientific quality and novelty of this discovery. This at
the same time implies a high likelihood of signing a lucrative licensing
agreement with a multinational leader in the field of DNA amplification and
next generation sequencing in the coming months.//
___________
For further information please contact:
SYGNIS AGAbout SYGNIS AG: www.sygnis.com
Pilar de la Huerta
CEO/CFO
Tel: +34-918063089
Email: pdelahuerta(at)sygnis.es
After the merger in 2012 between X-Pol Biotech, specializing in DNA
amplification and sequencing, and SYGNIS AG, listed in the German Stock
Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), SYGNIS'
new mission is to develop and distribute technologies and products from
X-Pol, which has a commercial product in the DNA amplification segment,
QualiPhi(R) and is currently developing other products in the field of Next
Generation Sequencing.
### Disclaimer
This publication is intended for information only and constitutes neither
an offer to sell nor an invitation to buy securities. Some statements
included in this press release, relating neither to proven financial
results nor other historical data, should be viewed as forward-looking,
i.e. not definite. Such statements are mainly predictions of future
results, trends, plans or goals. These statements should not be considered
to be total guarantees since given their very nature they are subject to
known and unknown risks and imponderability and can be affected by other
factors as a consequence of which the actual results, plans and goals of
SYGNIS AG may deviate greatly from the established conclusions or implied
predictions contained in such statements. SYGNIS does not undertake to
publicly update or revise these statements in the light of new information
or future results or for any other reason.###
End of Media Release
---------------------------------------------------------------------
Issuer: SYGNIS AG
Key word(s): Research/Technology
05.11.2013 Dissemination of a Press Release, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: SYGNIS AG
Im Neuenheimer Feld 515
69120 Heidelberg
Germany
Phone: 06221 454-6
Fax: 06221 454-700
E-mail: contact(at)sygnis.de
Internet: www.sygnis.de
ISIN: DE000A1RFM03
WKN: A1RFM0
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP-Media
---------------------------------------------------------------------
237939 05.11.2013
Themen in dieser Pressemitteilung:
sygnis-ag-molecular-cell-publishes-the-discovery-and-characterization-of-primpol
a-new-type-of-human-dna-polymerase
Unternehmensinformation / Kurzprofil:
Datum: 05.11.2013 - 13:17 Uhr
Sprache: Deutsch
News-ID 312691
Anzahl Zeichen: 7524
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 240 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"SYGNIS AG: Molecular Cell publishes the Discovery and Characterization of PrimPol, a new Type of Human DNA Polymerase"
steht unter der journalistisch-redaktionellen Verantwortung von
SYGNIS AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
